(Q39807470)

14 September 2017

title

Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation (English)

1 reference

14 September 2017

main subject

hepatocellular carcinoma

1 reference

1 reference

14 September 2017

Antonio Mazzocca

1 reference

14 September 2017

Emilia Fransvea

series ordinal

1 reference

14 September 2017

Gabriela Lavezzari

series ordinal

1 reference

14 September 2017

Salvatore Antonaci

series ordinal

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

page(s)

1140-1151

1 reference

Updated treatment approach to hepatocellular carcinoma.

14 September 2017

cites work

1 reference

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

7 January 2021

Angiogenesis and hepatocellular carcinoma

1 reference

7 January 2021

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

7 January 2021

Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis

1 reference

7 January 2021

Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors

1 reference

7 January 2021

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

7 January 2021

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

7 January 2021

Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells

1 reference

7 January 2021

Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma

1 reference

7 January 2021

Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma

1 reference

7 January 2021

Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin

1 reference

7 January 2021

Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion.

1 reference

7 January 2021

Protein microarrays: meeting analytical challenges for clinical applications.

1 reference

7 January 2021

Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays

1 reference

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

7 January 2021

Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study

1 reference

7 January 2021

Preoperative predictors of vascular invasion in hepatocellular carcinoma

1 reference

7 January 2021

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

7 January 2021

A sweet link between TGFbeta and vascular disease?

1 reference

7 January 2021

The complex pattern of SMAD signaling in the cardiovascular system

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23118

1 reference

release_52ohi6nonzamtghqhs2zccin4i

14 September 2017

Fatcat ID

0 references

1 reference